Le guide d’analyse d’impact budgétaire de la HAS : un nouvel outil d’aide à la décision

Abstract

The HAS BIA guidelines are expected to enhance the usefulness of BIA as an essential part of a comprehensive economic assessment of healthcare interventions, which itself includes cost-effectiveness analysis and equity of access to healthcare.

Estimated Costs Associated With Management of Otosclerosis With Hearing Aids vs Surgery in Europe

“…We compared a continuation of the current situation as a baseline scenario (scenario 1) with an alternative scenario (scenario 2) in which a greater proportion of patients would choose surgery rather than hearing aids (Figure 3). Contrary to guidelines recommending a single perspective, 39 we considered costs from 3 points of view, namely public health insurance, patients, and private health insurers, and overall. The costs of hearing aids are indeed often covered in large part by private health insurers and patients themselves, and this perspective is more internationally relevant.…”

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges

“…Since January 2016, in addition to the cost-effectiveness analysis (CEA) submissions, BIAs are required as part of efficiency dossiers submitted by manufacturers for innovative drugs with an expected 2-year sales revenue above 50 € million. A new HAS guideline for BIAs has been recently developed [4,5]. The short time since the implementation of the BIA process has not allowed evaluation of how BIA results might be used in the process of price negotiation.…”